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Summary
 
The T cell antigen receptor (TCR) and its ligand peptide–major histocompatibility complex
(MHC) are small (
 
z
 
7 nm) compared with other abundant cell surface molecules such as inte-
grins, CD43, and CD45 (23–50 nm). We have proposed that molecules at the T cell/antigen-
presenting cell (APC) interface segregate according to size, with small “accessory” molecules
(e.g., CD2, CD4, CD8, CD28, and CD154) contributing to the formation of a close-contact
zone, within which the TCR engages peptide–MHC, and from which large molecules are ex-
cluded (Davis, S.J., and P.A. van der Merwe. 1996. 
 
Immunol
 
.
 
 Today.
 
 17:177–187). One predic-
tion of this model is that increasing the size of these small accessory molecules will disrupt their
function. Here, we test this prediction by varying the dimensions of the CD2 ligand, CD48,
and examining how this affects T cell antigen recognition. Although the interaction of CD2 on
T cells with wild-type or shortened forms of CD48 on APCs enhances T cell antigen recogni-
tion, the interaction of CD2 with elongated forms of CD48 is strongly inhibitory. Further ex-
periments indicated that elongation of the CD2/CD48 complex inhibited TCR engagement
of peptide–MHC, presumably by preventing the formation of sufficiently intimate contacts at the
T cell/APC interface. These findings demonstrate the importance of small size in CD2/CD48
function, and support the hypothesis that T cell antigen recognition requires segregation of cell
surface molecules according to size.
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T
 
cell antigen recognition requires an interaction between
the TCR and a complex of peptide antigen with MHC
molecules (peptide–MHC) on the surface of APCs or tar-
get cells. This interaction takes place at the contact interface
between a T cell and an APC or target cell. It has been
pointed out (1, 2) that both the TCR (3, 4) and peptide–
 
MHC (5, 6) are unusually small (
 
z
 
7 nm) compared with
highly abundant cell surface molecules such as integrins
(
 
z
 
25 nm), CD43 (
 
z
 
43 nm), or CD45 (23–50 nm) (7). This
raises the question as to how the plasma membranes of the
T cell and APC or target cell form contacts that are suffi-
 
ciently intimate (
 
z
 
15 nm between membranes) for the TCR
to engage peptide–MHC (8, 9).
Several T cell “accessory” molecules implicated in antigen
recognition (e.g., CD2, CD4, CD8, CD28, and CD154) are
comparable in size to the TCR (7, 10). CD2 is arguably the
best characterized of these molecules (11–13). It has two
Ig-like domains in its extracellular portion (14, 15) and a
highly conserved proline-rich cytoplasmic domain that has
been shown to bind SH3 domains of cytoplasmic proteins
(16–18). The extracellular portion of CD2 mediates cell–
cell recognition by binding to CD58 (LFA-3) in humans
(19, 20) and CD48 in rodents (21, 22). CD2, CD48, and
CD58 are members of the CD2 family of Ig superfamily
molecules, which includes 2B4 and CD150 (SLAM) (13).
CD2 family members are structurally related and expressed
by linked genes (7, 23), suggesting that they have evolved
from a common ancestral molecule capable of homotypic
adhesion (24).
Although numerous studies have shown that the interac-
tion between CD2 and its ligands can enhance T cell anti-
gen recognition (12, 25, 26), the observation that CD2-
deficient mice have relatively mild abnormalities in T cell
development and T cell function (27–29) indicates that
CD2 is not indispensable. It has been suggested that T cells
are able to adapt during development to function in the ab- 
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sence of CD2 (by selection of a high-affinity TCR reper-
toire) or that other molecules can fulfill the same function
(27). Although there is convincing evidence that CD2 en-
hances T cell antigen recognition by mediating adhesion of
T cells to APCs or target cells (11, 12, 25), it may also
transduce signals through its cytoplasmic domain (12, 25,
26, 30). Structural (14) and mutagenesis (8) studies indicate
that CD2 binds to CD48 in a head-to-head orientation
such that the CD2/CD48 complex is likely to be of similar
length (
 
z
 
14 nm) to the TCR/peptide–MHC complex (3,
31). This has led to the proposal that the CD2/ligand inter-
action may facilitate T cell antigen recognition by partici-
pating in the formation of (a) close-contact zone(s) within
the contact interface between T cells and APCs or target
cells in which the intermembrane separation distance is op-
timal for TCR engagement of peptide–MHC (8, 9, 13).
Here, we test this hypothesis by varying the length of the
CD2 ligand, CD48, and examining the effect this has on T
cell antigen recognition. We show that whereas wild-type
or shortened CD48 enhanced T cell antigen recognition,
long forms of CD48 were profoundly inhibitory, prevent-
ing TCR engagement of peptide–MHC. These results dem-
onstrate the important role size plays in the accessory func-
tion of the CD2/CD48 interaction, and support the notion
that close membrane approximation (
 
,
 
21 nm) is a prereq-
uisite for T cell antigen recognition.
 
Materials and Methods
 
Cells and Antibodies.
 
The 2B4 T cell hybridoma and its deriv-
atives 2B4.CD2 (2B4.mCD2-1.6; transfected with full-length
mouse CD2) and 2B4.CD2trunc (2B4.mCD2.M3-2.1; transfected
with cytoplasmic tail–deleted mouse CD2) have been described
previously (26, 32). They were cultured in RPMI-10 medium
(RPMI 1640 [GIBCO BRL], 10% FCS [Sigma Chemical Co.],
100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin [GIBCO BRL],
4 mM glutamine [GIBCO BRL], and 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME [Sigma
Chemical Co.]). G418 (0.4 mg/ml; GIBCO BRL) was added to
medium used for 2B4.CD2 and 2B4.CD2trunc cells in order to
maintain expression of CD2. The Chinese hamster ovary (CHO)
 
1
 
cell line N1.A4 expressing mouse I-E
 
k 
 
has been described else-
where (33, 34). It was cultured in RPMI-10 medium containing
0.4 mg/ml G418 to maintain I-E
 
k
 
 expression.
The following mAbs were used: RM2-1, rat anti–mouse CD2,
IgG2a (35); OX11, rat anti–rat 
 
k
 
 chain, IgG2a (36, 37); OX78,
rat anti–mouse CD48, IgG2a (21); IE-D6, mouse anti–mouse
I-E
 
k
 
, IgG2a (Serotec); OX12, mouse anti–rat 
 
k
 
 chain, IgG2a
(36); 145-2C11, hamster anti–mouse-CD3 (38); A2B4-2, mouse
anti-2B4 TCR-
 
a
 
, IgG2a (39); and 30-H12, rat anti–mouse Thy1.2,
IgG2b (PharMingen).
 
Expression of CD48 Constructs in CHO Cells.
 
Four different
mouse CD48 constructs were made: wild-type CD48 with a silent
BssHII site NH
 
2
 
-terminal to the glycosyl phosphatidylinositol
(GPI) signal sequence for the insertion of additional domains;
elongated molecules with two-domain human CD2 (CD48-CD2)
 
or three-domain mouse CD22 (CD48-CD22) inserts; and a
shortened CD48 construct (CD48d1) in which the membrane-
proximal domain (d2) had been deleted (see Fig. 1 A). The wild-
type CD48 construct was made by PCR in two steps using as
template the vector pCD.MBCM-1, which contained the se-
quence for full-length mouse CD48 (23). In the first PCR, the 5
 
9
 
primer 1130 (tagtagtctagaccccatccgctcaagcaggccaccATGTGCTTC-
ATAAAACAGGGATGGTG) encoded an XbaI site (restriction
sites are underlined in all primers), the rat CD4 5
 
9
 
-untranslated
region (in lower case), and the first 26 nucleotides of the CD48
sequence beginning with the start codon (upper case; compare
with Wong et al. [23]). The 3
 
9
 
 primer GTTGTGACCACTA-
GCCAAGTTGCAGTCCAACATACTCCAGAAGAgCgcGC-
TAGATCACAAGGTAG encoded for the 3
 
9
 
 end of the second
domain of CD48, a silent restriction site (BssHII), and part of the
GPI anchor signal sequence. The resulting product was elongated in
a second PCR using the same 5
 
9
 
 primer (1130) with the 3
 
9
 
 primer
ctactagGaTCcTCAGGTTAACAaGATCCTGTGAATGATGA-
GTGTTGTGACCACTAGCCAAGTTGC. This primer over-
laps the 3
 
9
 
 primer used in the first PCR and encodes for the
remainder of the CD48 sequence followed by a BamHI site. In
addition, a silent mutation (lower case “a”) was introduced to
eliminate an internal BamHI site. The PCR product was digested
with XbaI and BamHI and ligated into vector pEF-BOS-XB (40).
To obtain a DNA fragment encoding domains 1 and 2 of hu-
man CD2 which could be inserted into the silent BssHII site in
the wild-type CD48 construct, a plasmid encoding the extracel-
lular portion of human CD2 (41) was used as template for a PCR
with the 5
 
9
 
 primer tagtaggcgcgcGAGATTACGAATGCCTTG-
GAAACC, which encodes a BssHII site and the CD2 signal
sequence (42), and the 3
 
9
 
 primer ctactagcgcgCTTTCTCTGGA-
CAGCTGACAGG, which encodes the final 21 nucleotides of
domain 2 (42) flanked by a BssHII site.
The mouse CD22 domain 1–3 insert was generated by PCR
using as template a plasmid encoding a CD22(d1–3) Fc chimera
with the mutation, R130A (43). The primers introduced flanking
BssHII sites: 5
 
9
 
 primer, tagtaggcgcgcGATTGGACCGTTGAC-
CATC; 3
 
9
 
 primer, ctactagcgcgcGTGCACCGTGAGTTCCAC.
The CD2 and CD22 fragments were cloned into the BssHII site
in the CD48 wild-type pEFBOS-XB plasmid. In the final con-
struct, the junctions at the CD2 insert were TGTGATCTA-
GCGCGCgagattacg and ccagagaaaGCGCGCTCTTCT (CD48
in upper case, CD2 in lower case, and BssHII site underlined).
Similarly, the junctions at the CD22 insert were GATCTAGC-
GCGCgattggacc and gtgcacGCGCGCTCTTCT.
The CD48d1 construct was obtained by PCR with the CD48
wild-type construct as template, using 1130 as 5
 
9
 
 primer and cta-
ctagcgcgCAGGATCAAATACTTCCAG as 3
 
9
 
 primer. The lat-
ter encoded for the last nucleotides of the membrane-distal do-
main of CD48 and added a BssHII site. The PCR product was
digested with XbaI and BssHII and inserted into the CD48 wild-
type pEFBOS-XB plasmid in place of the fragment encoding
CD48 d1 and 2. The boundary between domain 1 and the mCD48
GPI anchoring signal in the resulting construct was TTTGATC-
CTGCGCGCTCTTCT. All constructs were sequenced using an
Applied Biosystems DNA sequencing system (model 373A).
For expression, the CD48 constructs were subcloned into the
pEE14 expression vector using its XbaI and BclI sites (44, 45).
N1.A4 CHO cells were transfected and selected using the glu-
tamine synthetase selection system (44, 45). Stable lines were
selected at 15–40 
 
m
 
M 
 
l
 
-methyl sulfoximine (Sigma Chemical
Co.) and recloned. Clones which gave comparable staining with
CD48 mAb in cytometry analyses were chosen for functional as-
 
1
 
Abbreviations used in this paper:
 
 CHO, Chinese hamster ovary; GPI, gly-
cosyl phosphatidylinositol; ICAM, intercellular adhesion molecule;
MCC, moth cytochrome c. 
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says. They were maintained in culture in CB2-10 medium (CB-2
[GIBCO BRL], 10% dialyzed FCS [First Link], 100 U/ml peni-
cillin and 100 
 
m
 
g/ml streptomycin [GIBCO BRL], 0.4 mg/ml
G418 [Sigma Chemical Co.], and 15–40 
 
m
 
M 
 
l
 
-methyl sulfox-
imine). Revertants of the various clones were obtained by cultur-
ing cells for 8–12 wk in the absence of 
 
l
 
-methyl sulfoximine and
sorting for CD48
 
2
 
 cells on a FACSort™ cell sorter (Becton
Dickinson).
 
Western Blotting.
 
Triton X-100 lysates of 10
 
5
 
 CHO cells per
lane were separated by SDS-PAGE under reducing conditions and
transferred to nitrocellulose (Hybond-C-super; Amersham Phar-
macia Biotech). Membranes were probed with 1:7 dilutions of mAb
OX78 and OX11 spent tissue culture supernatant, followed by a
1:2,000 dilution of peroxidase-conjugated rabbit anti–rat Ig se-
rum (DAKO) and developed using the ECL
 
1
 
Plus system (Am-
ersham Pharmacia Biotech). Purified soluble mouse CD48 was
used as a positive control (46).
 
Flow Cytometry.
 
Standard procedures were used to stain cells
with purified mAbs (15 
 
m
 
g/ml) or hybridoma culture super-
natants. Binding of CD2 chimeric protein to CHO cells was
assessed using a previously described method developed for de-
tection of low-affinity interactions (47). In brief, 12.5 
 
m
 
l avidin-
coated fluorescent beads (YFP-0552-5; Spherotech) per sample
were rotated with 1.25 
 
m
 
g biotinylated anti–human Fc
 
g
 
 mAb
SB2H2 (47) and 40 
 
m
 
l of PBS/0.2% BSA for 45 min at 4
 
8
 
C,
washed in PBS/0.02% BSA, and rotated with 3 
 
m
 
g/ml of human
CD2 Fc (21) or human CTLA-4 Fc (48) for 2 h at 4
 
8
 
C in 1 ml of
RPMI-10 medium. Beads were washed and resuspended in 12.5
 
m
 
l PBS/BSA per sample, sonicated for 1 min, and added to 40 
 
m
 
l
PBS/BSA containing 10
 
5
 
 CHO cells in a well of a flat-bottomed
microtiter plate. Plates were centrifuged for 20 min at 1,000 rpm
at 4
 
8
 
C and incubated at 0
 
8
 
C for 40 min before the cells were re-
suspended in 0.5 ml PBS/BSA and analyzed in a FACScan
 
®
 
 flow
cytometer (Becton Dickinson).
Binding of CD48 to T cells was measured in a similar assay but
using a chimeric protein consisting of mouse CD48 fused to rat
CD4 domains 3 plus 4, followed by a short peptide tag which can
be enzymatically biotinylated (40). To create this construct, an
XhoI site was inserted 5
 
9
 
 of the His tag in a mouse sCD48his en-
coding plasmid (46) to enable the sCD48 portion to be excised
with XbaI and XhoI and cloned into the XbaI/SalI sites of a vec-
tor encoding rat CD4d3
 
1
 
4 and a consensus peptide sequence
recognized by the 
 
Escherichia coli
 
 biotin holoenzyme synthetase,
BirA (40). The CD48-CD4 boundary in the resulting chimera
was CTAGCCcgctcgacATCCATC. A rat CD5-CD4d3
 
1
 
4–bio-
tin construct was made in an analogous way. Both constructs
were expressed and biotinylated as described (40). The protein-
coated beads were prepared by rotating 12.5 
 
m
 
l of avidin-coated
fluorescent beads with 1 
 
m
 
g biotinylated protein in 350 
 
m
 
l PBS/
BSA for 1 h at 4
 
8
 
C, followed by washing, sonication, and cell la-
beling as described above.
 
T Cell Activation Assays.
 
In each well of a V-bottomed micro-
titer plate (Bibby Sterilin Ltd.), 5 
 
3
 
 10
 
4
 
 2B4 cells were mixed with
5 
 
3
 
 10
 
4
 
 irradiated (3,000 rad) CHO cell APCs and different con-
centrations of HPLC-purified moth cytochrome c (MCC) pep-
tide 88–103 (ANERADLIAYLKQATK; made by Dr. N.P.
Groome, Oxford Brookes University, Oxford, UK) and cultured
in RPMI-10 medium for 18 h. In some experiments, CHO cells
were preincubated with 10 
 
m
 
g/ml of mouse CD48 mAb OX78.
This concentration of mAb was maintained during the 2B4/
APC/peptide coculture. Subsequently, supernatants were har-
vested, and 2 
 
3
 
 10
 
4
 
 per well of IL-2–responsive CTLL-2 cells
(American Type Culture Collection) were cultured with serial
dilutions of the supernatants in RPMI-10 medium for 18 h. Puri-
fied recombinant mouse IL-2 was used as the standard (rec. mIL-2;
Boehringer Mannheim). Wells were pulsed with 0.5 
 
m
 
Ci/well of
[
 
3
 
H]thymidine (Amersham Pharmacia Biotech) and harvested af-
ter an additional 7 h. Linear regression (Cricket Graph; Com-
puter Associates International) was used to generate a linear fit,
which was used to calculate the unknown IL-2 concentrations.
Probably as a consequence of clonal variation, the different 2B4
cells exhibited somewhat different levels of antigen-induced IL-2
production even in the absence of CD2 ligation. This effect had
been noted previously in a study with T cells transfected with dif-
ferent forms of human CD2 (49). To allow comparison of the ef-
fects of CD48 expression on APCs between different 2B4 clones,
the results in some experiments were normalized, letting 100%
equal maximal peptide-stimulated IL-2 secretion in the presence
of CD48
 
2
 
 CHO cells.
For phorbol ester/calcium ionophore stimulation, peptide was
replaced with 50 ng/ml PMA (Sigma Chemical Co.) and 500
ng/ml ionomycin (Sigma Chemical Co.). For CD3 mAb stimu-
lation, flat-bottomed microtiter plates (Falcon) were incubated
with serum-free tissue culture supernatant containing CD3 mAb
145-2C11 for 2 h and washed with RPMI-10 before cells were
added and cultured as described above.
 
TCR Downmodulation Assay.
 
10
 
5
 
 CHO cell APCs were in-
cubated with MCC peptide 88–103 for 2 h in round-bottomed
Figure 1. Expression of elongated and
shortened forms of CD48 in I-Ek1 CHO
cells. (A) Schematic representation of the
various forms of CD48 used in this study.
Segments derived from mouse CD48 and
segments inserted from human CD2 or
mouse CD22 are depicted as heavy and light
lines, respectively. The asterisk represents the
CD22 mutation, R130A. (B) Western blot
of the CD48 constructs expressed on I-Ek1
CHO cells. Triton X-100 lysates of 105
I-Ek1 CHO cells expressing no CD48 (CD48
neg) or the indicated form of CD48 were
run under reducing conditions and blotted
with the mouse CD48 mAb, OX78. Soluble
recombinant mouse CD48 with an oligohis-
tidine tag (sCD48his, 50 ng) was included
for comparison. Parallel blots of the same
samples with an isotype-matched control
mAb (OX11) gave no staining (not shown). 
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microtiter plates before the addition of 5 
 
3
 
 10
 
4
 
 2B4.CD2 cells.
After coculture for 3 h at 37
 
8
 
C, the cells were resuspended in
PBS containing 0.5 mM EDTA and stained with anti-Thy1.2
and anti-2B4 TCR mAbs, followed by PE-conjugated goat anti–
rat IgG (Serotec) and FITC-conjugated goat anti–mouse IgG2a
(Southern Biotechnology Associates). TCR expression on the
Thy1.2
 
1
 
 cells (i.e., excluding the APCs) was measured using a
FACScan
 
®
 
 flow cytometer.
 
Results and Discussion
 
Expression of Elongated and Shortened Forms of CD48 on
APCs.
 
We examined the effect of varying the dimensions
of the CD2/ligand complex using an in vitro T cell antigen
recognition assay. The responder cells were the 2B4 mu-
rine MHC class II–restricted T cell hybridoma (26, 32, 50).
The 2B4 TCR recognizes a peptide fragment (88–103) of
MCC (MCC 88–103) bound to I-E
 
k
 
 (51). As APCs, we
used CHO cells expressing I-E
 
k
 
 (33). These I-E
 
k
 
1
 
 CHO
APCs were transfected with wild-type, elongated, or short-
ened forms of the mouse CD2 ligand, CD48 (Fig. 1 A). The
elongated forms of CD48 had either two (CD48-CD2) or
three (CD48-CD22) Ig domains inserted as spacers between
the membrane-proximal Ig domain of CD48 and its GPI
signal sequence (Fig. 1 A). The two-domain insert consisted
of the ectodomain of human CD2, whereas the three-
domain insert comprised the three membrane-distal Ig do-
mains of mouse CD22. Both these inserts are functionally
inert: human CD2 does not bind to mouse CD48 (46, 52),
and the CD22 insert has a point mutation (R130A) that
abolishes binding to its sialoglycoconjugate ligands (43). The
short form of CD48 (CD48d1) was produced by deleting
the membrane-proximal Ig domain (Fig. 1 A).
A Western blot of transfected I-E
 
k
 
1
 
 CHO cells using an
anti-CD48 mAb showed that the various CD48 constructs
migrated on SDS-PAGE at positions consistent with their
predicted molecular mass (Fig. 1 B). Transfected I-E
 
k
 
1
 
 CHO
clones that expressed equivalent levels of CD48 and H2-E
 
k
 
were selected for further analysis (Fig. 2 A). The exception
was CD48d1 I-E
 
k
 
1
 
 CHO cells, which expressed CD48 at
50% of the level of CD48 I-E
 
k
 
1
 
 CHO cells (Fig. 2 B).
Beads coated with mouse CD2 Fc (21) bound at least as
well to I-Ek1 CHO cells expressing elongated forms of
CD48 as to cells expressing wild-type CD48, indicating that
the CD48 remained functional (Fig. 2 A). In contrast,
binding of these beads to CD48d1 I-Ek1 CHO cells was
reduced by z90% (Fig. 2 B).
The Interaction between CD2 and Wild-type CD48 Enhances
T Cell Antigen Recognition. Although the interaction of hu-
man CD2 with its ligand, CD58, has been shown to enhance
T cell antigen recognition, such an effect has not been for-
mally demonstrated for the equivalent murine interaction
between CD2 and CD48. This is an important point be-
cause CD2-deficient mice have surprisingly mild alterations
in T cell function (27, 29), and the mouse and rat CD2/
CD48 interactions have an z6-fold lower solution affinity
(46, 53) and z40-fold lower membrane affinity (54) than
the human CD2/CD58 interaction (41). Therefore, we
examined the effect that CD48 expression on I-Ek1 CHO
cells had on antigen recognition by 2B4 T cells. Because
the original 2B4 hybridoma expressed only very low levels
of CD2 (Fig. 2 C), we used cells that had been stably trans-
fected with full-length mouse CD2 (2B4.CD2; reference
26). T cell antigen recognition by 2B4.CD2 cells, as mea-
sured by IL-2 secretion, was substantially enhanced by the
expression of CD48 on I-Ek1 CHO APCs (Fig. 3 A). This
enhancement was inhibited by incubating the APCs with a
blocking CD48 mAb (Fig. 4 C), and was lost in CD482 re-
vertants of these APCs (Fig. 3 A). In contrast, the CD48
mAb had no effect on the 2B4 cell response to CD482
Figure 2. Flow cytometry of APCs and T cells. (A) Comparison of
I-Ek1 CHO cell clones expressing wild-type and elongated forms of
CD48. In the left and center columns, cells were labeled with the OX78
(CD48) and IE-D6 (anti–I-Ek) mAbs (thick lines), respectively, or iso-
type-matched mAbs (left, OX11; middle, OX12) as controls (shaded). In
this analysis, OX78 binding was 15–20% lower on CD48-CD2 and
CD48-CD22 cells compared with CD48 I-Ek1 CHO cells. However, no
significant difference was measured in three other analyses (not shown).
In the right column, cells were labeled with mCD2-Fc–coated (bold line)
or hCTLA4-Fc–coated (shaded) fluorescein beads. (B) Comparison of
I-Ek1 CHO cells expressing wild-type and shortened CD48, as in A. (C)
Comparison of CD2 expression on the different 2B4 cell lines used. La-
beling by the CD2 (RM2-1) and the isotype-matched control (OX11)
mAbs is represented by bold lines and shaded histograms, respectively. All
2B4 cells expressed virtually identical levels of surface TCR (not shown).35 Wild et al.
Figure 3. The CD2/CD48 in-
teraction enhances T cell anti-
gen recognition. (A) Antigen
recognition by 2B4.CD2 cells
using as APCs untransfected
I-Ek1 CHO cells (CD48 neg
CHO), I-Ek1 CHO cells stably
transfected with CD48 (CD48
CHO), or CD482 revertant cells
derived from the latter clone
(CD48 CHO revertant). In each
well, 5 3 104 2B4.CD2 cells
were mixed with the same num-
ber of APCs and the indicated
concentrations of peptide. After
18 h of culture, supernatants
were analyzed for IL-2. Error
bars represent the SE of triplicate
cultures. (B) Comparison of anti-
gen recognition by 2B4 cells ex-
pressing high levels (2B4.CD2)
or very low levels (2B4) of CD2
using CD481 or CD482 I-Ek1
CHO cells as APCs. Experiment
performed as in A. The results
were normalized to aid compari-
son between the different 2B4
cells, letting 100% equal maximal
peptide-stimulated IL-2 secretion
in the presence of CD48 neg CHOs. (C) Comparison of antigen recognition by 2B4 cells expressing full-length (2B2.CD2) or truncated
(2B4.CD2trunc) forms of CD2 cells with CD481 or CD482 I-Ek1 CHO cells as APCs. Experiment performed as in A. (D) Binding of CD48-coated
beads to 2B4.CD2 cells is blocked by a CD2 mAb. 2B4.CD2 T cells were incubated with a mouse CD2 (RM2-1) or control (OX11) mAb before incu-
bation with CD5- (control) or CD48-coated fluorescent beads, followed by flow cytometry. Identical results were obtained with 2B4.CD2trunc T cells.
I-Ek1 CHO cells (Fig. 4 C) nor on the CTLL line used in
the IL-2 assay (data not shown), indicating that the inhibi-
tory effect was not the result of binding to 2B4 or CTLL-2
cells (which also express CD48). The CD48 mAb consis-
tently inhibited IL-2 secretion to below the levels seen
with CD482 I-Ek1 CHO cells (Fig. 4 C). This may be be-
cause mAb treatment killed up to 30% of CD481 I-Ek1
CHO cells (data not shown).
Recently, the CD2-like 2B4 molecule has been shown
to be a second ligand for CD48 (40), raising the question as
to whether the CD48 on I-Ek1 CHO cells was interacting
with the 2B4 molecules on 2B4 cells. It was not possible to
use a blocking CD2 mAb to test this because ligation of
CD2 with mAb appears to transduce an inhibitory signal in
2B4 cells (26). However, two observations indicate that the
enhancement by CD48 involves binding to CD2 alone.
First, the enhancement was much reduced in 2B4 cells ex-
pressing very low levels of CD2 (Fig. 3 B), and second, the
binding of CD48-coated beads to 2B4 cells is completely
blocked by anti-CD2 mAbs (Fig. 3 D).
Although these results clearly demonstrate that an inter-
action between CD2 on T cells and CD48 on APCs can
substantially enhance T cell antigen recognition, they do
not reveal the mechanism of this effect. In addition to be-
ing an adhesion molecule, there is evidence that CD2 may
transduce signals that activate T cells in the human (55) and
the rat (30) or inhibit T cells in the mouse (26). Signaling
through CD2 can be abolished by truncation of its cyto-
plasmic domain (12, 25, 26, 30). We found that CD48 is also
able to enhance antigen recognition by 2B4 cells that ex-
press a truncated form of mouse CD2 lacking all but 19 of
the 116 amino acids normally present in the cytoplasmic
domain (Fig. 3 C). Studies using truncated forms of mouse,
rat, and human CD2 indicate that this truncation abolishes
antibody-induced signaling (12, 25, 26, 30). These results
indicate that the enhancing effect of the CD2/CD48 inter-
action is at least partly a consequence of improved adhesion.
Indeed, recent studies (17, 56) suggest that the weaker en-
hancing effect observed with truncated CD2 may reflect a
role for the cytoplasmic domain in enhancing adhesion rather
than in transducing a signal.
Long Forms of CD48 Inhibit the T Cell Antigen Recognition.
In striking contrast to the effect of wild-type CD48, trans-
fection of I-Ek1 CHO APCs with long forms of CD48
inhibited T cell antigen recognition (Fig. 4 A). It is notable
that the slightly longer form of CD48, CD48-CD22, showed
greater inhibition than CD48-CD2 (Fig. 4 A). CD48-CD22
had the larger inhibitory effect in seven out of eight inde-
pendent antigen response assays (data not shown). The sin-
gle exception is shown in Fig. 4 D, where CD48-CD2 and
CD48-CD22 inhibit to a similar extent. 2B4 cells express-
ing very low levels of CD2 exhibited only very weak inhi-
bition (Fig. 4 B), consistent with an effect mediated by
CD2 ligation. Blocking anti-CD48 antibodies reversed the
inhibitory effect of elongated CD48 (Fig. 4 C). This rever-
sal was partial, possibly because the anti-CD48 antibody
killed a proportion of the CD48-expressing I-Ek1 CHO cells
(not shown). Finally, the inhibitory effect was completely lost
in CD482 revertants derived from the CD48-CD2– and
CD48-CD22–transfected I-Ek1 CHO cells (Fig. 4 D).36 Molecular Dimensions and T Cell Antigen Recognition
with a shortened form of CD48 (CD48d1; Fig. 1 A) en-
hanced peptide–MHC-induced activation of 2B4 (Fig. 6).
Enhancement by CD48d1 was observed with 2B4 cells ex-
pressing both full-length (Fig. 6 A) and truncated (Fig. 6 B)
CD2, but was somewhat reduced compared with wild-type
CD48 (Fig. 6). Because the surface expression of CD48d1
was only half that of CD48 (Fig. 2 B), and CD2 binding to
these cells was also substantially reduced (Fig. 2 B), it is not
possible to deduce from these data how much less effective
CD48d1 is than full-length CD48 at enhancing T cell anti-
gen recognition. Nevertheless, it is clear that shortening of
CD48 does not have the same inhibitory effect as elonga-
tion. This is an important control, since both shortening
and elongation of CD48 would be expected to disrupt cis-
interactions with other surface molecules. It follows that
elongation of CD48 cannot be inhibiting by disrupting
such  cis-interactions.
Long Forms of CD48 Inhibit TCR Downmodulation. To
further investigate the mechanism by which long forms of
CD48 inhibited T cell antigen recognition, we investigated
the effect of elongated CD48 on TCR downmodulation.
Recent studies suggest that TCR downmodulation is a con-
sequence of TCR engagement (57, 58), and is relatively in-
dependent of costimulation and downstream signaling events.
Although wild-type CD48 enhanced TCR downmodula-
tion induced by peptide-loaded I-Ek1 CHO cells, CD48-
CD22 strongly inhibited downmodulation (Fig. 7). This sug-
These findings strongly suggest that the inhibitory effect
is a consequence of CD2 ligation by the elongated forms of
CD48, but do not indicate the mechanism of the inhibi-
tion. Since CD2 has been reported to transduce inhibitory
signals when cross-linked with mAbs (26), it was important
to exclude that inhibitory signaling through CD2. 2B4 cells
expressing the truncated form of CD2 (2B4.CD2trunc),
which does not transduce an inhibitory signal (26), was also
inhibited by expression of elongated CD48 (Fig. 4 B). We
also examined whether long forms of CD48 are inhibitory
when T cells are activated by mechanisms that do not re-
quire peptide–MHC ligation. When 2B4.CD2trunc cells
were activated with a phorbol ester plus ionomycin (Fig. 5 A)
or an immobilized anti-CD3 mAb (Fig. 5 B), CHO cells
expressing long forms of CD48 had no inhibitory effect.
Similar results were obtained with 2B4 cells expressing full-
length CD2 (not shown). Thus, the inhibitory effect of
elongated CD48 was only evident when T cells were acti-
vated by TCR engagement of peptide–MHC. Taken to-
gether, these results indicate that the inhibitory effect of
elongated CD48 is not a consequence of negative signaling
through CD2.
A Shortened Form of CD48 Enhances the T Cell Antigen
Recognition. We next examined the effect of shortening
CD48. Because CD48 has only two Ig domains, it was only
possible to shorten it by a single domain (z3.5 nm). In con-
trast to the long forms of CD48, transfection of I-Ek1 CHO
Figure 4. Elongated forms of
CD48 inhibit T cell antigen rec-
ognition. (A) Antigen recogni-
tion by 2B4.CD2 cells using as
APCs I-Ek1 CHO cells expressing
no CD48 (CD48 neg CHO),
wild-type CD48 (CD48 CHO),
CD48-CD2, or CD48-CD22.
The assay was performed as de-
scribed in the legend to Fig. 3 A.
The error bars for cultures con-
taining CD48-CD2 and CD48-
CD22 I-Ek1 CHO cells are
smaller than the triangular symbols
and cannot be seen. (B) CD48-
CD2 or CD48-CD22 inhibit an-
tigen recognition by 2B4 cells ex-
pressing full-length (2B2.CD2) or
truncated (2B4.CD2trunc) CD2.
Assay performed as in A with 10
mM peptide. (C) The stimulatory
effects of CD48 and inhibitory ef-
fects of CD48-CD2 and CD48-
CD22 are reversed by a blocking
CD48 mAb. Assay performed as
in A with 1 mM peptide except
that before the assay, the I-Ek1
CHO cells were incubated for 1 h
with 10 mg/ml of the CD48 mAb
OX78 and the mAb included
throughout the assay. The back-
ground response (in the absence
of peptide) was subtracted from all values. In B and C, the results were normalized to aid comparison between the different 2B4 cells, letting 100% equal max-
imal peptide-stimulated IL-2 secretion in the presence of CD48 neg CHOs. (D) Revertant (CD482) cells derived from the CD48-CD2 and CD48-CD22
I-Ek1 CHO clones do not inhibit the antigen response of 2B4.CD2trunc cells. Revertant cells expressed the same levels of I-Ek as their parent clones (not
shown). Assay performed as in A.37 Wild et al.
gests that wild-type CD48 enhances, whereas elongated
CD48 inhibits, TCR engagement of peptide–MHC.
Inhibition of TCR/Peptide–MHC Interaction by Elongation
of the CD2/CD48 Complex. The key observation in this
study is that whereas expression of wild-type CD48 on
APCs enhances T cell antigen recognition, CD48 elon-
gated by two or three Ig-like domains is strongly inhibi-
tory. The most likely explanation for these results, strongly
supported by measurements of TCR downmodulation
(Fig. 7), is that binding of CD2 on T cells to elongated
forms of CD48 on APCs positions the plasma membranes
at a distance too far apart for efficient TCR engagement of
peptide–MHC (Fig. 8, right). Conversely, the binding of
CD2 to wild-type CD48 promotes TCR/peptide–MHC
engagement through a favorable positioning of the plasma
membranes (Fig. 8, left). Control experiments have excluded
several other explanations. Thus, the inhibitory effect is not
the result of negative signaling through CD2, nor is it likely
Figure 6. A shortened form of CD48 is able to enhance T cell antigen
recognition. Assay performed as in the legend to Fig. 3 A using as re-
sponders 2B4 cells expressing either full-length (2B4.CD2) or truncated
(2B4.CD2trunc) forms of CD2, and as APCs I-Ek1 CHO cells expressing
no CD48 (CD48 neg CHO), wild-type CD48, or shortened CD48
(CD48d1 CHO).
Figure 7. Elongated CD48 inhibits TCR downmodulation. TCR
downmodulation was measured by flow cytometry on 2B4.CD2 cells
after coculture with the indicated I-Ek1 CHO cell APCs loaded with
various concentrations of MCC peptide. Downmodulation is expressed as
the percent reduction in mean TCR levels, with 0% downmodulation
equal to the TCR level measured in the absence of peptide. The values
shown are the mean 6 SD of triplicate cultures. Data shown are repre-
sentative of three independent experiments.
Figure 8. A model explaining the contrasting effects of wild-type and
elongated CD48 on T cell antigen recognition. CD2 molecules on T cells
and CD48 molecules on I-EK1 CHO APCs interact to form contacts in
which the intermembrane separation distance is determined by the di-
mensions of the CD2/CD48 complex. Wild-type CD48 (left) enhances
T cell antigen recognition because the separation distance (z15 nm) is
optimal for TCR engagement of peptide–MHC. Elongated CD48
(CD48-CD22, right) inhibits T cell antigen recognition by forming con-
tacts in which the intermembrane distance (.20 nm) is too great for
TCR to engage peptide–MHC.
Figure 5. Elongated CD48 molecules do not inhibit the response of T
cells to antigen-independent stimuli. (A) CHO cells with elongated
CD48 do not inhibit T cell activation by PMA/ionomycin. Assay per-
formed as in the legend to Fig. 3 A except that, instead of peptide anti-
gen, PMA (50 ng/ml) plus ionomycin (500 ng/ml) was used to stimulate
2B4.CD2trunc T cells. (B) CHO cells with elongated CD48 do not in-
hibit T cell activation by CD3 mAb. Assay performed as in the legend to
Fig. 3 A except that, instead of peptide antigen, CD3 mAb 145-2C11 was
immobilized to microtiter plates (see Materials and Methods) before addi-
tion of 2B4.CD2trunc T cells and APCs. Similar results were obtained
when soluble 145-2C11 was used to stimulate the T cells (not shown).38 Molecular Dimensions and T Cell Antigen Recognition
to be a consequence of the disruption of cis-interactions be-
tween CD48 and other molecules. Although our data indi-
cate that TCR/peptide–MHC engagement is inhibited, we
cannot formally exclude the possibility that elongated forms
of CD48 also inhibit T cell antigen recognition by forcing
the segregation of CD2 from the TCR, thereby sequester-
ing CD2-associated molecules required for TCR signaling.
CD2 and the “Kinetic-segregation” Model of T Cell Antigen
Recognition. The human CD2 fragment inserted into the
CD48-CD2 chimera is z7 nm long (15). Since the length
of the CD2/CD48 complex is z14 nm (8), the CD2/CD48-
CD2 complex will span 14–21 nm. If the proposed expla-
nation for the inhibitory effects of elongated CD48 is cor-
rect (Fig. 8), our data imply that optimal TCR engagement
of peptide–MHC requires that the plasma membranes of
the T cell and APC have to be ,21 nm apart. It follows
that molecules larger than this (e.g., CD45 and CD43), and
molecular interactions that span greater distances (e.g.,
LFA-1/intercellular adhesion molecule [ICAM]-1), would
need to be excluded from the immediate vicinity of the
TCR when it engages peptide–MHC.
Our results thus provide support for a model proposed
by Davis and van der Merwe (henceforth called the “kinetic-
segregation” model) for T cell antigen recognition (13).
This model postulates that molecules in the contact area be-
tween T cells and APC/target cells will segregate according
to size, and that this segregation is a prerequisite for TCR
triggering. The concept of segregation of T cell surface mol-
ecules according to size was first introduced by Springer
(10). A similar model has been also been proposed recently by
Shaw and Dustin (9). The kinetic-segregation model postu-
lates that small molecules such as CD2, CD4, CD8, CD28,
and CD154 will localize, together with their extracellular and
cytoplasmic ligands, in zones of especially intimate contact
(z15 nm between membranes) called “close-contact zones,”
and that larger molecules such as integrins, CD43, and CD45
would be excluded from these zones. It is proposed that
TCR binding to peptide–MHC leads to TCR triggering
by trapping the TCR/CD3 complex within the tyrosine
kinase–enriched (and tyrosine phosphatase–deficient) close-
contact zone for a period of time sufficient for tyrosine
phosphorylation of TCR/CD3-associated signaling mole-
cules. Several lines of evidence support this model. First,
intermembrane distances of 12–15 nm have been measured
in the contact area between cytotoxic T cells and target cells
(59). Second, Kupfer and colleagues (60) have shown that
TCR/CD3 and the integrin LFA-1 are segregated into dif-
ferent regions at the T cell/APC interface. Third, Dustin et
al. (17) have shown that when Jurkat cells are allowed to
adhere to lipid-anchored CD48 and ICAM-1 (CD54, an
LFA-1 ligand) inserted into glass-supported planar lipid bi-
layers, the ICAM-1 and CD48 segregate from each other in
the contact area. Fourth, Sperling et al. (61) have reported
that CD43 is completely excluded from the binding inter-
face between T cells and APCs. Interestingly, CD45 was not
excluded from the binding interface, and was sometimes
polarized towards it (61). Higher resolution imaging studies
will be required to determine whether, like LFA-1 (17, 60),
CD45 segregates from the TCR within the interface. Fi-
nally, our finding that elongation of CD2/CD48 complexes
to the approximate size of an integrin molecule (z21 nm)
inhibits T cell antigen recognition provides experimental
support for the notion that segregation is a prerequisite for
TCR engagement of peptide–MHC.
Our findings raise the question as to why large cell–cell ad-
hesion molecules such as the integrin LFA-1 do not inhibit T
cell antigen recognition through the same mechanism as pos-
tulated here for the elongated forms of CD48. Indeed, LFA-1
interactions appear to enhance TCR engagement of peptide–
MHC (62). One possible explanation, strongly supported by
recent data (60), is that T cells have evolved specific mecha-
nisms, perhaps cytoskeletally driven (63), to actively segregate
LFA-1 from the TCR within the contact zone. This would
enable LFA-1 to participate in T cell–APC conjugate forma-
tion without physically interfering with TCR binding to
peptide–MHC. In contrast, there is evidence that CD2 may
be actively clustered within the contact zone into the imme-
diate vicinity of the TCR (17). This would be expected to
prevent the segregation of elongated CD2/CD48 complexes
from the site of TCR engagement.
Since CD48d1 is missing a single Ig domain (z3.5 nm),
it can reasonably be predicted that the CD2/CD48d1 com-
plex will be z3.5 nm shorter than the CD2/CD48 com-
plex (i.e., z10.5 nm). Our finding that CD48d1 can still
enhance T cell antigen recognition implies that some re-
duction in the size of accessory molecules (and thus inter-
membrane distance) can be tolerated. Mechanisms by which
the TCR/peptide–MHC interaction could adjust to closer
membrane approximation include compression of long
stalk regions of the TCR, which lack secondary structure,
or tilting of the TCR/peptide–MHC complex relative to
the plane of the membrane. Some limited flexibility in the
size of accessory molecule and TCR/peptide–MHC com-
plexes may be important because it is unlikely that all mo-
lecular interactions involved in T cell antigen recognition
will span exactly the same distance.
The kinetic-segregation model postulates that small ac-
cessory molecules contribute to T cell antigen recognition
in part by driving the formation of intimate close-contact
zones. While the CD2/ligand interaction may contribute
to the formation of close-contact zones, any accessory mol-
ecule interaction with approximately the same dimensions
could fulfill the same function. This is supported by the ob-
servation that CD2-deficient mice have very mild abnor-
malities in T cell function (27, 29). Candidate accessory
molecules include CD28/ligand interactions and interac-
tions involving other members of the CD2 family. The do-
main composition of CD28 and its ligands CD80 and CD86
suggests that these interactions will span 10–15 nm (7). Al-
though CD28 can transduce activation signals through its
cytoplasmic region (64), the recent observation that a form
of CD28 lacking a cytoplasmic domain is very effective at
enhancing T cell antigen recognition (65) provides strong
support for an important adhesion role. Structural and mu-
tagenesis studies suggest that interactions between other
CD2 family members will span the same distance as the39 Wild et al.
CD2/CD48 complex (13, 46), making them suitable for
membrane approximation in T cell antigen recognition.
Potential candidates include SLAM (66), which is expressed
on T cells, and 2B4, which is expressed on NK cells and a
subpopulation of T cells (67, 68), and has recently been
shown to bind CD48 (40).
In conclusion, our results demonstrate the importance of
accessory molecule size, and suggest that close membrane
approximation is required for T cell antigen recognition. This
and other recent studies (17, 60, 61) support models of T
cell antigen recognition (9, 13) which propose that the cell
surface molecules segregate according to size at the T cell/
APC interface, and that this segregation is required for
TCR engagement and triggering.
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